In order to comply with the NfG on Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections (CPMP/ EWP/ 558/ 95 rev.1), the applicant accepted that proposed SPC should be updated in due time to include EUCAST breakpoints.